Your browser doesn't support javascript.
loading
Treatment of metastatic cutaneous Crohn disease with certolizumab.
Kiuru, Maija; Camp, Brendan; Adhami, Katayun; Jacob, Vinita; Magro, Cynthia; Wildman, Horatio.
Afiliación
  • Kiuru M; University of California Davis, Sacramento. mkiuru@ucdavis.edu.
Dermatol Online J ; 21(11)2015 Nov 18.
Article en En | MEDLINE | ID: mdl-26632928
ABSTRACT
Metastatic Crohn disease is a rare cutaneous manifestation of Crohn disease characterized by granulomatous lesions discontinuous with the diseased areas of the gastrointestinal tract. We report a case of a 32-year-old woman with history of Crohn disease who was admitted for treatment of cellulitis after presenting with a tender erythematous plaque of the left calf. Microbiological tests including tissue cultures were negative. A skin biopsy revealed granulomatous dermatitis consistent with metastatic cutaneous Crohn disease. Owing to concomitant perianal fistulas and abscesses and prior infusion reaction to infliximab, the patient was treated with certolizumab, a pegylated tumor necrosis factor (TNF) inhibitor combined with methotrexate resulting in complete resolution of the skin lesion. This case emphasizes the importance of recognizing this rare skin manifestation of Crohn disease and adds certolizumab as one of TNF inhibitors useful in the treatment of metastatic cutaneous Crohn disease.
Asunto(s)
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Enfermedades de la Piel / Enfermedad de Crohn / Factor de Necrosis Tumoral alfa / Certolizumab Pegol / Inmunosupresores Límite: Adult / Female / Humans Idioma: En Revista: Dermatol Online J Asunto de la revista: DERMATOLOGIA Año: 2015 Tipo del documento: Article
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Enfermedades de la Piel / Enfermedad de Crohn / Factor de Necrosis Tumoral alfa / Certolizumab Pegol / Inmunosupresores Límite: Adult / Female / Humans Idioma: En Revista: Dermatol Online J Asunto de la revista: DERMATOLOGIA Año: 2015 Tipo del documento: Article